Tissue Regenix Group PLC

Full interview: Tissue Regenix to boost production capacity as its sees strong global demand for its products

Tissue Regenix Group PLC's (LON:TRX) Gareth Jones tells Proactive London's Andrew Scott they're focused on initiatives to increase capacity and alleviate supply constraints as they continue to see strong demand for its products.

Sales rose £500,000 to £6.1mln during the six months ended June 30, boosted by revenues from its DermaPure skin repair product, which grew by 33% to £2mln.

Quick facts: Tissue Regenix Group PLC

Price: £0.03

Market: AIM
Market Cap: £39.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...



Tissue Regenix building its capabilities for future sustainable delivery

Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught up with Proactive's Andrew Scott to discuss the group's interim 2018 results. In the six months to the end of June they inked distribution agreements with Arthrex and ARMS Medical of the US and Pennine...

on 3/9/18

2 min read